Display options
Cite
Mosoni C, Dionisi T, Vassallo GA, et al. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Front Psychiatry. 2018;9:474doi: 10.3389/fpsyt.2018.00474.
Mosoni, C., Dionisi, T., Vassallo, G. A., Mirijello, A., Tarli, C., Antonelli, M., Sestito, L., Rando, M. M., Tosoni, A., De Cosmo, S., Gasbarrini, A., & Addolorato, G. (2018). Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Frontiers in psychiatry, 9474. https://doi.org/10.3389/fpsyt.2018.00474
Mosoni, Carolina, et al. "Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence." Frontiers in psychiatry vol. 9 (2018): 474. doi: https://doi.org/10.3389/fpsyt.2018.00474
Mosoni C, Dionisi T, Vassallo GA, Mirijello A, Tarli C, Antonelli M, Sestito L, Rando MM, Tosoni A, De Cosmo S, Gasbarrini A, Addolorato G. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Front Psychiatry. 2018 Oct 01;9:474. doi: 10.3389/fpsyt.2018.00474. eCollection 2018. PMID: 30327620; PMCID: PMC6174362.
Copy Download .nbib Format: NLM
Share it on

Front Psychiatry. 2018 Oct 01;9:474. doi: 10.3389/fpsyt.2018.00474. eCollection 2018.

Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence.

Frontiers in psychiatry

Carolina Mosoni, Tommaso Dionisi, Gabriele Angelo Vassallo, Antonio Mirijello, Claudia Tarli, Mariangela Antonelli, Luisa Sestito, Maria Margherita Rando, Alberto Tosoni, Salvatore De Cosmo, Antonio Gasbarrini, Giovanni Addolorato

Affiliations

  1. "Alcohol Use Disorder and Related Disease" Unit, Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy.
  2. Department of Internal Medicine and Gastroenterology, Catholic University of Rome, Rome, Italy.
  3. Emergency Department, V. Cervello Hospital, Palermo, Italy.
  4. Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.

PMID: 30327620 PMCID: PMC6174362 DOI: 10.3389/fpsyt.2018.00474

Abstract

Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver disease. Medical recommendations, brief motivational interventions and psychosocial approach are essential pieces of the treatment for these patients; however, their efficacy alone may not be enough to achieve total alcohol abstinence. The addition of pharmacological treatment could improve clinical outcomes in AUD patients. Moreover, pharmacological treatments for AUD are limited in patients with advanced liver disease, since impaired liver function affects drugs metabolism and could increase the risk of drugs-related hepatotoxicity. At present, only baclofen has been tested in RCTs in patients with advanced liver disease. This medication was effective to reduce alcohol intake, to promote alcohol abstinence and to prevent relapse in AUD patients affected by liver cirrhosis. In addition, the drug showed a safe profile in these patients. In this review, clinical studies about efficacy and safety of baclofen administration in patients with AUD and advanced liver disease will be reviewed. Open question about the most appropriate dose of the drug, duration of the treatment and need of additional studies will also be discussed.

Keywords: GABA-B receptor; alcohol use disorder; alcoholic liver disease; baclofen; liver cirrhosis

References

  1. Alcohol Res Health. 2003;27(1):39-51 - PubMed
  2. Addict Behav. 2012 Apr;37(4):561-4 - PubMed
  3. J Clin Psychopharmacol. 2012 Apr;32(2):266-8 - PubMed
  4. Alcohol. 2017 Aug;62:11-15 - PubMed
  5. J Hepatol. 2014 Sep;61(3):642-59 - PubMed
  6. Lancet. 2007 Dec 8;370(9603):1915-22 - PubMed
  7. Transplantation. 2016 May;100(5):981-7 - PubMed
  8. Gastroenterol Clin Biol. 1992;16(8-9):687-91 - PubMed
  9. J Hepatol. 2018 Aug;69(2):461-511 - PubMed
  10. Alcohol Alcohol. 2014 Jul-Aug;49(4):453-6 - PubMed
  11. Alcohol Clin Exp Res. 2011 May;35(5):848 - PubMed
  12. Am J Med. 2006 Mar;119(3):276.e13-8 - PubMed
  13. J Hepatol. 2016 Sep;65(3):618-30 - PubMed
  14. J Hepatol. 2018 Jul;69(1):154-181 - PubMed
  15. Br J Psychiatry. 2018 Jun;212(6):362-369 - PubMed
  16. Drugs. 2015 Mar;75(4):353-65 - PubMed
  17. Hepatology. 2007 Dec;46(6):2032-9 - PubMed
  18. Nat Rev Gastroenterol Hepatol. 2014 May;11(5):300-7 - PubMed
  19. Alcohol Alcohol. 2011 Nov-Dec;46(6):714-20 - PubMed
  20. Neuropsychobiology. 2005;51(2):59-66 - PubMed
  21. Biomed J. 2016 Feb;39(1):72-80 - PubMed
  22. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):33-44 - PubMed
  23. Semin Liver Dis. 1988 Feb;8(1):91-102 - PubMed
  24. Curr Pharm Des. 2010;16(19):2113-7 - PubMed
  25. Eur J Gastroenterol Hepatol. 2017 Oct;29(10):1155-1160 - PubMed
  26. Addiction. 2017 Jul;112(7):1173-1183 - PubMed
  27. J Hosp Med. 2011 Oct;6(8):469-74 - PubMed
  28. Alcohol Alcohol. 2011 May-Jun;46(3):312-7 - PubMed
  29. Alcohol Alcohol. 2012 Jul-Aug;47(4):439-42 - PubMed

Publication Types